StockLumo

Cingulate Inc. (CING): Form 8-K filed 2026-11-13

Accepted by EDGAR
2026-11-13 17:19 ET
Event date
2026-11-13
Accession no.
0001493152-26-051841
Original filing
SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Cingulate reports third-quarter results, updates CTx-1301 resubmission and adds ATM agent

Cingulate reported a quarterly net loss of $7.7 million and approximately $23.2 million in cash and cash equivalents as of September 30, 2026. It said manufacturing work addressing FDA information requests for CTx-1301 was substantially completed and expects NDA resubmission between December 2026 and January 2027. The company also added Maxim Group LLC as an agent under its existing ATM Agreement.

earningsregulatoryequity offering

Items reported

Documents

TypeDescriptionDocument
8-K8-Kform8-k.htm
EX-10.1EX-10.1ex10-1.htm
EX-99.1EX-99.1ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.